Acadia Pharma (NASDAQ: ACAD) reported Q1 EPS of $0.02, $0.03 worse than the analyst estimate of $0.05. Revenue for the quarter came in at $268.06 million versus the consensus estimate of $280.92 million.

GUIDANCE:

Acadia Pharma sees FY2026 revenue of $1.22-1.28 billion, versus the consensus of $1.23 billion.

For earnings history and earnings-related data on Acadia Pharma (ACAD) click here.